The Amyloidosis Program
The Amyloid Treatment and Research Program at Boston University School of Medicine, under the direction of
David C. Seldin, M.D., Ph.D., is recognized internationally as a leader in basic and clinical research on amyloidosis. Our mission is to serve as a:
- Referral center for evaluation and treatment of patients with amyloid diseases
- International resource for information on amyloidosis for scientists, physicians, and patients
- Reference laboratory for diagnosis of rare forms of amyloidosis
- Coordinating center for clinical trials and laboratory research on systemic amyloidosis.
The Program is unique in its combination of research, both basic and clinical research and patient care. Activities in the Alan and Sandra Gerry Amyloid Research Laboratory are directed by Lawreen Connors, Ph.D. and include basic research on amyloid projects that involve collaborative efforts with other laboratories at Boston University and elsewhere.
The Amyloid Clinical Program under the direction of John Berk, M.D., coordinates the multidisciplinary evaluation of patients with amyloidosis that are seen at Boston Medical Center by subspecialists who are expert in amyloid disease. The Clinical Program works closely with the Stem Cell Transplant Program in the Section of
Hematology-Oncology, directed by Vaishali Sanchorawala, M.D., and with the Clinical Trials Office, directed by Kathy Finn, RN, NP. Trials and treatment are available for all major forms of amyloidosis.